IL17A and colitis: In conclusion, DBK successfully reduced inflammation in DSS-induced UC mice by modulating the IL-6/IL-6R and IL-17A/IL-17RA pathways, as evidenced by alleviated colitis symptoms, decreased pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and histological improvements.